MEDINDIA
English
हिन्दी
Español
français
中文
PLAINSBORO, N.J., Aug. 18, 2025
PLAINSBORO, N.J., Aug. 18, 2025 /PRNewswire/ -- Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved Ozempic® (semaglutide) for $499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for Ozempic® and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay."Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk. While Ozempic® is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine. We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "This is why we felt it was important to make Ozempic®, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, more affordable to those without insurance who deserve the real thing."
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of blood sugar, along with diet and exercise, in adults with type 2 diabetes, risk reduction of major cardiovascular events such as heart attack, stroke, or death in adults also with known cardiovascular (CV) disease, lowering the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to CV disease in adults who also have chronic kidney disease.1 Today, millions of people have taken Ozempic®2 in the US to help address these chronic conditions, yet there are still some without adequate coverage seeking improved access.
The offer is available through multiple platforms so that patients with a prescription for real, FDA-approved Ozempic® can access it in the way that suits them best. For the first time, Ozempic® is available through NovoCare® Pharmacy, which offers convenient home delivery, while the offer is also available via Ozempic.com and NovoCare.com.
In addition, Novo Nordisk is collaborating with GoodRx, the leading platform for medication savings in the U.S., to offer both Wegovy® (for adults with obesity3) and Ozempic® (for adults with type 2 diabetes1) at $499 per month through the GoodRx platform, making this price available to eligible self-paying patients at more than 70,000 pharmacies nationwide. The relationship with GoodRx is another example of Novo Nordisk teaming up with healthcare companies who have a shared commitment to driving access and affordability for patients seeking Novo Nordisk's authentic, FDA-approved medicines for their approved uses.
Novo Nordisk is continuing to take multiple proactive measures to keep patients aware of potentially unsafe and unapproved knockoff alternatives and informed of how to access authentic, FDA-approved medicines. More information can be found on semaglutide.com.
About NovoCare® Pharmacy NovoCare® Pharmacy (CoAssist Pharmacy d/b/a NovoCare® Pharmacy) provides cash-paying patients with the ability to schedule shipments of certain prescriptions directly to their home. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare.com.
What is Ozempic®?
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:
It is not known if Ozempic® is safe and effective for use in children.
Important Safety Information
Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
What is the most important information I should know about Ozempic®?
Ozempic® may cause serious side effects, including:
Do not use Ozempic® if:
Before using Ozempic®, tell your health care provider if you have any other medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.
What are the possible side effects of Ozempic®?
Ozempic® may cause serious side effects, including:
The most common side effects of Ozempic® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.
Please click here for Prescribing Information and Medication Guide for Ozempic®.
About Wegovy® (semaglutide) injection 2.4 mg
What is Wegovy®?
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Important Safety Information
What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including:
Do not use Wegovy® if:
Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please click here for Prescribing Information and Medication Guide for Wegovy®.
About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
Media:
Liz Skrbkova (US) +1 609 917 0632
[email protected]
Ambre James-Brown (Global) +45 3079 [email protected]
Investors:
Frederik Taylor Pitter (US)
+1 609 613 [email protected]
Jacob Martin Wiborg Rode (Global) +45 3075 [email protected]
Sina Meyer (Global)
+45 3079 6656 [email protected]
Ida Schaap Melvold (Global)
+45 3077 5649 [email protected]
Max Ung (Global) +45 3077 [email protected]
References
1. Ozempic® (semaglutide) injection [package insert]. Plainsboro, NJ: Novo Nordisk Inc.2. Data on File.3. Wegovy® (semaglutide) injection [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.Ozempic® is a registered trademark of Novo Nordisk A/S. Wegovy® is a registered trademark of Novo Nordisk A/S.© 2025 Novo Nordisk All rights reserved. US25OZM00781 August 2025
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-lowers-cost-of-ozempic-to-499-per-month-for-self-paying-patients-in-support-of-patient-access-to-authentic-fda-approved-semaglutide-medicines-302532208.html
SOURCE Novo Nordisk
